Publications
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine, Second Faculty of Medicine
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation?2019 | Faculty of Medicine in Hradec Králové
- Treatment of repeatedly relapsing chronic lymphocytic leukemia2018 | Faculty of Medicine in Hradec Králové
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Primary testicular lymphoma2017 | Faculty of Medicine in Hradec Králové
- Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Practical approach to management of chronic lymphocytic leukemia2016 | Faculty of Medicine in Hradec Králové
- Treatment of patients with recurrent/refractory aggressive non-Hodgkin's lymphoma: effectiveness and safety of pixantrone2016 | Faculty of Medicine in Hradec Králové
Loading network view...